Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone

Pharmacology Biochemistry and Behavior

Volumn 89, Issue 4, 2008, Pages 515-522

  Dean, Reginald L ^a   Todtenkopf, Mark S ^a   Deaver, Daniel R ^a   Arastu, Mahin F ^a   Dong, Nan ^a   Reitano, Krystal ^a   O'Driscoll, Kevin ^a   Kriksciukaite, Kristina ^a   Gastfriend, David R ^a  

^a ALKERMES INC   (United States)

Author keywords

Analgesia; Antinociception; Fentanyl; Hydrocodone; Locomotor activity; Morphine; PLG microspheres; Respiration rate; Vivitrol ; XR NTX

Indexed keywords

FENTANYL; HYDROCODONE; MORPHINE; NALTREXONE; OPIATE; PLACEBO;

ALCOHOLISM; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; BREATHING RATE; DOSE RESPONSE; DRUG RELEASE; HOT PLATE TEST; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING;

ALCOHOLISM; ANALGESICS, OPIOID; ANIMALS; DELAYED-ACTION PREPARATIONS; DRUG INTERACTIONS; FENTANYL; HUMANS; HYDROCODONE; MALE; MORPHINE; MOTOR ACTIVITY; NALTREXONE; NARCOTIC ANTAGONISTS; PAIN; PAIN MEASUREMENT; PLETHYSMOGRAPHY, WHOLE BODY; RATS; RATS, SPRAGUE-DAWLEY; RESPIRATION;

RATTUS;

EID: 41949101288     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2008.02.006     Document Type: Article

References (39)

1. Babbini M., and Davis W.M. Time-dose relationships for locomotor activity effects of morphine after acute or repeated treatment. Br J Pharmacol 46 (1972) 213-224
2. Baranczewski P., Stanczak A., Kautiainen A., Sandin P., and Edlund P.O. Introduction to early in vitro identification of metabolites of new chemical entities in drug discovery and development. Pharmacol Rev 58 (2006) 341-352
3. Baros A.M., Latham P.K., Moak D.H., Voronin K., and Anton R.F. What role does measuring medication compliance play in evaluating the efficacy of naltrexone?. Alcohol Clin Exp Res 31 (2007) 596-603
4. Bartus R.T., Emerich D.F., Hotz J., Blaustein M., Dean R.L., Perdomo B., et al. Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats. Neuropsychopharmacology 28 (2003) 1973-1982
5. Borgbjerg F.M., Nielsen K., and Franks J. Experimental pain stimulates respiration and attenuates morphine-induced respiratory depression: a controlled study in human volunteers. Pain 64 (1996) 123-128
6. Borison H.L. Central nervous respiratory depressants-narcotic analgesics. Pharmacol Ther [B] 3 (1977) 227-237
7. Brewer C. Serum naltrexone and 6-beta-naltrexol levels from naltrexone implants can block very large amounts of heroin: a report of two cases. Addict Biol 7 (2002) 321-323
8. Cicero T.J., Nock B., and Meyer E.R. Sex-related differences in morphine's antinociceptive activity: relationship to serum and brain morphine concentrations. J Pharmacol Exp Ther 282 (1997) 939-944
9. Comer S.D., Sullivan M.A., Yu E., Rothenberg J.L., Kleber H.D., Kampman K., et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 63 (2006) 210-218
10. Dean R.L. The preclinical development of Medisorb Naltrexone, a once a month long acting injection, for the treatment of alcohol dependence. Front Biosci 10 (2005) 643-655
11. Dunbar J.L., Turncliff R.Z., Dong Q., Silverman B.L., Ehrich E.W., and Lasseter K.C. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone. Alcohol Clin Exp Res 30 (2006) 480-490
12. Eckenhoff J.E., and Oech S.R. The effects of narcotics and antagonists upon respiration and circulation in man. A review. Clin Pharmacol Ther 1 (1960) 483-524
13. Garbutt J.C., Kranzler H.R., O'Malley S.S., Gastfriend D.R., Pettinati H.M., Silverman B.L., et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 293 (2005) 1617-1625
14. Green A.F. Comparative effects of analgesics on pain threshold, respiratory frequency and gastrointestinal propulsion. Br J Pharmacol Chemother 14 (1959) 26-34
15. Harris K.M., DeVries A., and Dimidjian K. Datapoints: trends in naltrexone use among members of a large private health plan. Psychiatr Serv 55 (2004) 221
16. He G.A., Hou H.M., and Liu X.J. Naltrexone microspheres: in vitro release and effect on morphine analgesia in mice. Acta Pharmacol Sin 22 (2001) 530-533
17. Hulse G.K., Arnold-Reed D.E., O'Neil G., Chan C.T., Hansson R., and O'Neil P. Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants. Addict Biol 9 (2004) 59-65
18. Hulse G.K., Tait R.J., Comer S.D., Sullivan M.A., Jacobs I.G., and Arnold-Reed D. Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants. Drug Alcohol Depend 79 (2005) 351-357
19. Inturrisi C.E. Clinical pharmacology of opioids for pain. Clin J Pain 18 (2002) S3-S13
20. Johnson B.A., Ait-Daoud N., Aubin H.J., Van Den Brink W., Guzzetta R., Loewy J., et al. A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence. Alcohol Clin Exp Res 28 (2004) 1356-1361
21. Lalley P.M. Mu-opioid receptor agonist effects on medullary respiratory neurons in the cat: evidence for involvement in certain types of ventilatory disturbances. Am J Physiol Regul Integr Comp Physiol 285 (2003) R1287-R1304
22. Lee M.C., Wagner Jr. H.N., Tanada S., Frost J.J., Bice A.N., and Dannals R.F. Duration of occupancy of opiate receptors by naltrexone. J Nucl Med 29 (1988) 1207-1211
23. McLaughlin C.R., and Dewey W.L. A comparison of the antinociceptive effects of opioid agonists in neonatal and adult rats in phasic and tonic nociceptive tests. Pharmacol Biochem Behav 49 (1994) 1017-1023
24. Meert T.F., and Vermeirsch H.A. A preclinical comparison between different opioids: antinociceptive versus adverse effects. Pharmacol Biochem Behav 80 (2005) 309-326
25. Navaratnam V., Jamaludin A., Raman N., Mohamed M., and Mansor S.M. Determination of naltrexone dosage for narcotic agonist blockade in detoxified Asian addicts. Drug Alcohol Depend 34 (1994) 231-236
26. O'Brien B., and Cody C. Analgesia and sedation in the presence of a naltrexone implant: a novel pharmacological challenge. Eur J Emerg Med 13 (2006) 315-316
27. O'Malley S.S., Garbutt J.C., Gastfriend D.R., Kranzler H.R., Pettinati H.M., Illeperuma M.S., et al. Effects of lead-in abstinence and a goal in abstinence on heavy drinking. Alcohol Clin Exp Res 29 (2005) 77A
28. Pettinati H.M., and Rabinowitz A.R. Choosing the right medication for the treatment of alcoholism. Curr Psychiatry Rep 8 (2006) 383-388
29. Pettinati H.M., Volpicelli J.R., Pierce Jr. J.D., and O'Brien C.P. Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis 19 (2000) 71-83
30. Raehal K.M., Walker J.K., and Bohn L.M. Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Ther 314 (2005) 1195-1201
31. Schug S.A., Zech D., and Grond S. Adverse effects of systemic opioid analgesics. Drug Safety 7 (1992) 200-213
32. Schuh K.J., Walsh S.L., and Stitzer M.L. Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans. Psychopharmacology (Berl) 145 (1999) 162-174
33. Shook J.E., Watkins W.D., and Camporesi E.M. Differential roles of opioid receptors in respiration, respiratory disease, and opiate-induced respiratory depression. Am Rev Respir Dis 142 (1990) 895-909
34. Tambour S., and Quertemont E. Preclinical and clinical pharmacology of alcohol dependence. Fundam Clin Pharmacol 21 (2007) 9-28
35. Verebey K., Volavka J., Mule S.J., and Resnick R.B. Naltrexone: disposition, metabolism, and effects after acute and chronic dosing. Clin Pharmacol Ther 20 (1976) 315-328
36. Vickers A.P., and Jolly A. Naltrexone and problems in pain management. BMJ 332 (2006) 132-133
37. Walker J.K., and Jennings D.B. Respiratory effects of pressor and depressor agents in conscious rats. Can J Physiol Pharm 76 (1998) 707-714
38. Yaksh T. Central pharmacology of nociceptive transmission. In: Wall P., and Melzack R. (Eds). Textbook of Pain (1999), Churchill Livingstone, London 253-308
39. Yoburn B.C., Cohen A.H., and Inturrisi C.E. Pharmacokinetics and pharmacodynamics of subcutaneous naltrexone pellets in the rat. J Pharmacol Exp Ther 237 (1986) 126-130